MCID: VST006
MIFTS: 27

Vestibulocochlear Nerve Disease

Categories: Ear diseases, Neuronal diseases

Aliases & Classifications for Vestibulocochlear Nerve Disease

MalaCards integrated aliases for Vestibulocochlear Nerve Disease:

Name: Vestibulocochlear Nerve Disease 12 14
Vestibulocochlear Nerve Diseases 41 69
Cochlear Nerve Diseases 69
Acoustic Nerve Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12657
ICD10 32 H93.3 H93.3X
ICD9CM 34 388.5
MeSH 41 D000160
NCIt 46 C27207
SNOMED-CT 64 194402005 77949003

Summaries for Vestibulocochlear Nerve Disease

MalaCards based summary : Vestibulocochlear Nerve Disease, also known as vestibulocochlear nerve diseases, is related to vestibular neuronitis, and has symptoms including tinnitus and earache. An important gene associated with Vestibulocochlear Nerve Disease is RTEL1 (Regulator Of Telomere Elongation Helicase 1). The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotype is Synthetic lethal with vaccinia virus (VACV) infection.

Wikipedia : 72 The vestibulocochlear nerve (auditory vestibular nerve), known as the eighth cranial nerve, transmits... more...

Related Diseases for Vestibulocochlear Nerve Disease

Diseases related to Vestibulocochlear Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 vestibular neuronitis 7.9 CACNA1A PIR RTEL1 SALL1 SLC9C1 VSIR

Symptoms & Phenotypes for Vestibulocochlear Nerve Disease

UMLS symptoms related to Vestibulocochlear Nerve Disease:


tinnitus, earache

GenomeRNAi Phenotypes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 CACNA1A PIR SALL1

Drugs & Therapeutics for Vestibulocochlear Nerve Disease

Drugs for Vestibulocochlear Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4 Antiemetics Phase 4,Phase 3
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
6 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
7 Autonomic Agents Phase 4,Phase 3
8 Gastrointestinal Agents Phase 4,Phase 3
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Methylprednisolone acetate Phase 4,Phase 3
14 Methylprednisolone Hemisuccinate Phase 4,Phase 3
15 Neuroprotective Agents Phase 4,Phase 3
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
17 Prednisolone acetate Phase 4,Phase 3
18 Prednisolone hemisuccinate Phase 4,Phase 3
19 Prednisolone phosphate Phase 4,Phase 3
20 Protective Agents Phase 4,Phase 3
21 Anti-Bacterial Agents Phase 4,Phase 2,Early Phase 1
22 Anti-Infective Agents Phase 4,Phase 2,Early Phase 1
23 Gentamicins Phase 4
24 Anti-Asthmatic Agents Phase 4,Phase 3
25 Betamethasone benzoate Phase 4
26 Betamethasone sodium phosphate Phase 4
27 Betamethasone Valerate Phase 4 2152-44-5
28 Betamethasone-17,21-dipropionate Phase 4
29 Respiratory System Agents Phase 4,Phase 3
30 Ophthalmic Solutions Phase 4
31 Tetrahydrozoline Phase 4
32
Ethanol Approved Phase 3 64-17-5 702
33
Cilostazol Approved, Investigational Phase 3 73963-72-1 2754
34
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
35 Complement System Proteins Phase 3
36 Micronutrients Phase 3
37 Trace Elements Phase 3
38 Ubiquinone Phase 3
39 Vitamins Phase 3
40 Fibrinolytic Agents Phase 3,Phase 2
41 Platelet Aggregation Inhibitors Phase 3,Phase 2
42 Bronchodilator Agents Phase 3
43 Phosphodiesterase 3 Inhibitors Phase 3
44 Phosphodiesterase Inhibitors Phase 3
45 Vasodilator Agents Phase 3
46 Ginkgo Nutraceutical Phase 3
47 Lecithin Nutraceutical Phase 3
48
Everolimus Approved Phase 2,Early Phase 1 159351-69-6 6442177
49
Miconazole Approved, Investigational, Vet_approved Phase 2,Early Phase 1 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 2,Early Phase 1 53123-88-9 46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 75)

# Name Status NCT ID Phase Drugs
1 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4 Betamethasone;Placebo;Prednisolone
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
4 Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy Terminated NCT02373397 Phase 4
5 The Efficacy of Steroid Therapy in Vestibular Neuritis Unknown status NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
8 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
9 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
10 Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy Terminated NCT01895400 Phase 3 Renexin (cilostazol 100mg + gingko biloba extract 80 mg);Placebo
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
12 Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System Completed NCT00032383 Phase 1, Phase 2
13 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
14 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
15 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
16 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
17 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
18 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
19 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
20 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
21 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2 Icotinib
22 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
23 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
24 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Active, not recruiting NCT02831257 Phase 2 AZD2014
25 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2 Bevacizumab
26 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Active, not recruiting NCT01345136 Phase 2 RAD001, everolimus
27 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
28 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2 Aspirin;Placebo
29 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2 PTC299
30 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2 Nilotinib
31 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
32 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
33 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1 Bevacizumab (Avastin)
34 Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs) Unknown status NCT02463695
35 The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis Unknown status NCT01231009 Early Phase 1 Corticosteroids
36 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231
37 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
38 Vestibular System in Migrainous Vertigo Patients Unknown status NCT00901953
39 Concentration and Activity of Lapatinib in Vestibular Schwannomas Unknown status NCT00863122 Early Phase 1 lapatinib
40 NF2 Natural History Consortium Unknown status NCT00004483
41 Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users Completed NCT00725998
42 Optimizing the Ocular Surface Prior to Cataract Surgery Completed NCT02766907
43 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896 gentamicin
44 Home-based Computer Gaming in Vestibular Rehabilitation Completed NCT01943955
45 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099
46 Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype Completed NCT02298270
47 Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool Completed NCT02171312
48 Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients Completed NCT01222728
49 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216
50 MRIPositive Diagnosis of Vestibular Neuritis Using Fluid Attenuated Inversion Recuperation (FLAIR) Sequence on a 1.5 Tesla Recruiting NCT03452410

Search NIH Clinical Center for Vestibulocochlear Nerve Disease

Cochrane evidence based reviews: vestibulocochlear nerve diseases

Genetic Tests for Vestibulocochlear Nerve Disease

Anatomical Context for Vestibulocochlear Nerve Disease

MalaCards organs/tissues related to Vestibulocochlear Nerve Disease:

38
Brain, Testes, Liver

Publications for Vestibulocochlear Nerve Disease

Articles related to Vestibulocochlear Nerve Disease:

# Title Authors Year
1
Facial and vestibulocochlear nerve disease in six horses. ( 6643213 )
1983

Variations for Vestibulocochlear Nerve Disease

Expression for Vestibulocochlear Nerve Disease

Search GEO for disease gene expression data for Vestibulocochlear Nerve Disease.

Pathways for Vestibulocochlear Nerve Disease

GO Terms for Vestibulocochlear Nerve Disease

Molecular functions related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 8.62 CACNA1A SLC9C1

Sources for Vestibulocochlear Nerve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....